Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

Response Pharmaceuticals26 enrolled

Overview

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

1. Office seated peripheral systolic and diastolic blood pressure 2. Adverse events and vital signs 3. Plasma concentrations of SLx-2101

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Hypertension

Interventions

SLx-2101DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or females between 18 and 80 years, inclusive * Moderate to severe hypertension * Body weight within a body mass index range of 18 - 32 kg/m2 Exclusion Criteria: * Subject is receiving more than four antihypertensive agents * History of drug abuse * Exposure to a new chemical entity within 3 months prior to the first day of dosing

Locations (1)

Addenbrooke's Hospital

Cambridge, United Kingdom

Outcomes

Primary Outcomes

Office seated peripheral systolic and diastolic blood pressure

Time frame: 12 days

Secondary Outcomes

Adverse events and changes in vital signs

Time frame: 12 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.